The short version of LY3437943 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-17 and is reviewed periodically as new material appears.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
=== Surgery === Weight loss surgery in those with obesity and type 2 diabetes is often an effective measure. Many are able to maintain normal blood sugar levels with little or no medications following surgery and long-term mortality is decreased. There is, however, a short-term mortality risk of less than 1% from the surgery. The body mass index cutoffs for when surgery is appropriate are not yet clear. It is recommended that this option be considered in those who are unable to get both their weight and blood sugar under control. A pancreas transplant is occasionally considered for people with type 1 diabetes who have severe complications of their disease, including end stage kidney disease requiring kidney transplantation. Diabetic peripheral neuropathy (DPN) affects 30% of all diabetes patients. When DPN is superimposed with nerve compression, DPN may be treatable with multiple nerve decompressions. The theory is that DPN predisposes peripheral nerves to compression at anatomical sites of narrowing, and that the majority of DPN symptoms are actually attributable to nerve compression, a treatable condition, rather than DPN itself. The surgery is associated with lower pain scores, higher two-point discrimination (a measure of sensory improvement), lower rate of ulcerations, fewer falls (in the case of lower extremity decompression), and fewer amputations.
The Bristol Brabazon was a large trans-Atlantic airliner built in the late 1940s, based on developments in heavy bombers during World War II, but it received no sales orders and never went into production. Concorde, the first supersonic airliner was built in the 1960s, first flying in 1969. The aircraft never achieved commercial success, but its development did lay the foundation for the successful Airbus series of airliners, parts of which are produced at Filton in the 21st century. In the 1980s the financial services sector became a major employer in the city and surrounding areas, such as the business parks on the northern fringe of what was now referred to as Greater Bristol or the Bristol Urban Area comprising the city, Easton-in-Gordano, Frampton Cottrell and Winterbourne, Kingswood, Mangotsfield and Stoke Gifford. High technology companies such as IBM, Hewlett Packard, Toshiba, and Orange, along with creative and media enterprises become significant local employers as traditional manufacturing industries declined. Like much of British post-war planning, regeneration of Bristol city centre was characterised by large, cheap tower blocks, brutalist architecture and expansion of roads. Since the 1990s this trend has been reversed, with the closure of some main roads and the regeneration of the Broadmead shopping centre. In 2006 one of the city centre's tallest post-war blocks was torn down. Social housing tower blocks have also been demolished to be replaced by low rise homes.
== External links == Lisa Cross Official Biography Lisa Cross Biography Archived 10 August 2012 at the Wayback Machine 2009 UKBFF Hercules Competition Photographs 2009 NABBA England Results Archived 18 September 2010 at the Wayback Machine - Miss Physique, 2nd 2009 NABBA Universe Results Archived 18 September 2010 at the Wayback Machine - Miss Physique, 2nd 2010 UKBFF British Championships Results Archived 22 November 2010 at the Wayback Machine - Ladies Physique, 1st FLEX Magazine (British Edition, April 2010) Archived 16 November 2010 at the Wayback Machine
Sources: en.wikipedia.org
Trump names himself as the headliner for the "Great American State Fair" semiquincentennial event, organized by Freedom 250, in Washington D.C., after several artists pull out over concerns that the event became politicized by Trump. Martina McBride, Young MC, Bret Michaels, and the Commodores were among the artists who pulled out. A revised lineup includes artists such as Flo Rida, Milli Vanilli, and Vanilla Ice. May 31 – The National Basketball Association announces that the logo for the Larry O'Brien Championship Trophy will be displayed on the basketball courts of Frost Bank Center in San Antonio, Texas, and Madison Square Garden in New York City for the upcoming NBA Finals between the San Antonio Spurs and New York Knicks, making it the first time the logo decal will be placed on the NBA court during the NBA Finals since 2009.
=== Bossa and Vertigo === By September 2017, Faliszek had joined London-based Bossa Studios, and led Bossa's new Seattle-based studio. He was working on an unannounced cooperative game that is "trying to do something new in the narrative space using [artificial intelligence]". In May 2018, Faliszek announced he had also joined the board of advisers for Vertigo Games, and will help support a virtual reality title they are currently developing. After about a year at Bossa, Faliszek and Bossa agreed that what Faliszek had planned was not working out, in part due to his envisioned game not being the type of product Bossa had worked on before, and Faliszek left the company early in 2019. By March 2019, he founded a new studio, Stray Bombay Company, along with Riot Games' Kimberly Voll, in essence to continue the development of the cooperative title. Faliszek had previously met Voll around 2012 while Valve was exploring the VR space, and had helped Voll get Radial Games Fantastic Contraption as a SteamVR launch title. Faliszek found Voll's focus on player interaction a key part of his idea for the cooperative game. Stray Bombay was backed financially by both Riot and Upfront Ventures. The company's first game is The Anacrusis, which was released via early access in January 2022, and fully launched December 5th, 2023. Starting around 2023, Faliszek began to post TikToks and YouTube videos about his time at Valve, experiences in the games industry, and his views on game design. He would make a video about Stop Killing Games, disagreeing with the movement.
Dapagliflozin can cause low blood sugar when combined with insulin. To lessen the risk of developing ketoacidosis after surgery, the US FDA approved changes to the prescribing information for SGLT-2 inhibitors to recommend they be stopped temporarily before scheduled surgery. Canagliflozin, dapagliflozin, and empagliflozin should each be stopped at least three days before, and ertugliflozin should be stopped at least four days before scheduled surgery. The glucose-lowering effect of dapagliflozin starts to diminish in people with chronic kidney disease with reduced kidney function (eGFR <45mL/min) and may not be as effective for glycemic control. However, studies have demonstrated a renoprotective effect in reducing kidney function decline, dapagliflozin can still be used to reduce kidney function decline regardless of diabetes status. Therefore, while dapagliflozin can be used in people with diabetes and chronic kidney disease to prevent kidney function decline, further interventions may be needed for glycemic control.
Sources: en.wikipedia.org
==== Emerging foodborne pathogens ==== Aeromonas hydrophila, Aeromonas caviae, Aeromonas sobria Scandinavian outbreaks of Yersinia enterocolitica have recently increased to an annual basis, connected to the non-canonical contamination of pre-washed salad.
Waschkies et al. studied the structure of dilute to concentrated freeze-casts from low (< 1 μm s−1) to extremely high (> 700 μm s−1) solidification velocities. From this study, they were able to generate morphological maps for freeze-cast structures made under various conditions. Maps such as these are excellent for showing general trends, but they are quite specific to the materials system from which they were derived. For most applications where freeze-casts will be used after freezing, binders are needed to supply strength in the green state. The addition of binder can significantly alter the chemistry within the frozen environment, depressing the freezing point and hampering particle motion leading to particle entrapment at speeds far below the predicted vc. Assuming, however, that we are operating at speeds below vc and above those which produce a planar front, we will achieve some cellular structure with both ice-crystals and walls composed of packed ceramic particles. The morphology of this structure is tied to some variables, but the most influential is the temperature gradient as a function of time and distance along the freezing direction. Freeze-cast structures have at least three apparent morphological regions. At the side where freezing initiates is a nearly isotropic region with no visible macropores dubbed the Initial Zone (IZ). Directly after the IZ is the Transition Zone (TZ), where macropores begin to form and align with one another. The pores in this region may appear randomly oriented.
== June 7, 1915 (Monday) == Battle of Hébuterne — The French 2nd Army attacked German positions around Hébuterne, France to support the 10th Army efforts further north at Artois. French troops were able to overrun the first two German lines during the opening day. The Dardanelles Committee met in London decided to reinforce the Mediterranean Expeditionary Force of General Ian Hamilton with three divisions from Kitchener's Army in an attempt to reinvigorate the Gallipoli campaign. The first German Army Zeppelin airship was destroyed in air-to-air combat by British pilot Reginald Warneford of No. 1 Squadron over Ghent, Belgium. The airship crashed in Sint-Amandsberg, Belgium, killing one person on the ground and all but one of the crew. Warneford received the Victoria Cross for the action. The LZ 38, the first Zeppelin P Class airship of the Imperial German Army, was destroyed when British planes bombed the shed it was housed in near Evere, Belgium. The first airship flew out of Friedrichshafen-Löwental airfield near Friedrichshafen, Germany. Born: Dominic Bruce, British air force officer, member of the No. 9 and No. 214 Squadrons during World War II, noted escapee from German POW camp Oflag IV-C at Colditz Castle, recipient of the Order of the British Empire, Order of St. Gregory the Great, Military Cross, and Air Force Medal; in Hebburn, England (d. 2000) Graham Ingels, American comic book artist, best known for his work for EC Comics; in Cincinnati, United States (d.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.